Hansa Biopharma — Februar 2026
-
Analysts and consensus | Hansa Biopharma
We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.
(www.hansabiopharma.com)
-
Conference Call Details
Hansa Biopharma will host a telephone conference today Wednesday, 11 February 2026, at 14:00 CET / 8:00 am EST.
Join the webcast here:
Registration | Hansa Biopharma Fourth Quarter 2025 Earnings
Hansa Biopharma Fourth Quarter 2025 Earnings
(event.choruscall.com)
-
Relativ volumen var 83% i dag, og VWAP ligger på 37,48 mod seneste handel i 35,90. Det ligner lidt, at træet er blevet rystet for at tage nogle stop-loss. Som LP90 også har skrevet før, er der et ret tydeligt mønster omkring 40-niveauet, så man kan jo svinge lidt med en del af positionen, hvis man har lyst. Med en FDA-godkendelse i sigte burde casen egentlig løfte sig, men FDA virker noget uforudsigelig for tiden.
-
18/2
Hansa Biopharma’s Biologics License Application (BLA) for imlifidase accepted by the FDA https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma-s-biologics-license-application--bla--for-imlifidase-accepted-by-the-fda,c4309758 -
exitnu tak for dine altid beroligende ord jeg forstår bare ikke den her case den har så svært ved at komme ud af starthullerne tænk sig den har været i
kurs 336 og nu kan den ikke kommer over 40 ??? PS har købt mere de sidste 2 dage 1.000 stk. i fri og pension men nu må den fandme godt snart flyve
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind